Co-Authors
This is a "connection" page, showing publications co-authored by ASHISH KAMAT and CHARLES CHUANHAI GUO.
Connection Strength
5.558
-
Contribution of bladder cancer pathology assessment in planning clinical trials. Urol Oncol. 2021 10; 39(10):713-719.
Score: 0.650
-
Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int. 2024 Feb 19.
Score: 0.247
-
Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2024 Feb; 211(2):241-255.
Score: 0.242
-
Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.
Score: 0.238
-
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci. 2023 Jul; 53:16-22.
Score: 0.234
-
Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy: Implications for survivorship. Urol Oncol. 2023 02; 41(2):108.e11-108.e17.
Score: 0.227
-
Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. 2022 08 04; 158(2):263-269.
Score: 0.222
-
Reply by Authors. J Urol. 2022 08; 208(2):290-291.
Score: 0.221
-
All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Gu?rin Response in High-Grade Ta Tumors. J Urol. 2022 08; 208(2):284-291.
Score: 0.221
-
Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. BJU Int. 2022 11; 130(5):604-610.
Score: 0.212
-
Reply by Authors. J Urol. 2021 11; 206(5):1267.
Score: 0.207
-
Progression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021 11; 206(5):1258-1267.
Score: 0.206
-
Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol. 2020 07 07; 154(2):208-214.
Score: 0.192
-
Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.
Score: 0.177
-
Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 09; 79:57-65.
Score: 0.166
-
High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol. 2017 09; 67:126-133.
Score: 0.157
-
Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506.
Score: 0.154
-
Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810.
Score: 0.145
-
Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016 10; 70(4):611-620.
Score: 0.143
-
Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Gu?rin Therapy: Implication for Clinical Trial Design. Eur Urol. 2016 11; 70(5):778-785.
Score: 0.142
-
Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec; 46(12):1808-14.
Score: 0.137
-
Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71.
Score: 0.130
-
Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34.
Score: 0.129
-
Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014 Jul; 45(7):1466-72.
Score: 0.124
-
Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009 Oct; 40(10):1448-52.
Score: 0.089
-
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
Score: 0.060
-
Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.
Score: 0.056
-
Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2022 04; 20(2):176-182.
Score: 0.053
-
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.
Score: 0.053
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.049
-
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
Score: 0.048
-
What Is the Significance of Variant Histology in Urothelial Carcinoma? Eur Urol Focus. 2020 07 15; 6(4):653-663.
Score: 0.045
-
Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol. 2019 01; 75(1):8-10.
Score: 0.043
-
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2019 05; 2(3):286-293.
Score: 0.042
-
Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583.
Score: 0.039
-
Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017 05; 119(5):684-691.
Score: 0.037
-
Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9.
Score: 0.020